|Home | About | Journals | Submit | Contact Us | Français|
Previous studies identified NADPH oxidases (Nox) and mitochondrial electron transport chain at complex I as major cellular sources of reactive oxygen species (ROS) mediating systemic and cellular responses to intermittent hypoxia (IH). In the present study, we investigated potential interactions between Nox and the mitochondrial complex I and assessed the contribution of mitochondrial ROS in IH-evoked elevation in blood pressure. IH treatment led to stimulus-dependent activation of Nox and inhibition of complex I activity in rat pheochromocytoma (PC)12 cells. After re-oxygenation, Nox activity returned to baseline values within 3h, whereas the complex I activity remained downregulated even after 24h. IH-induced complex I inhibition was prevented by Nox inhibitors, Nox2 but not Nox 4 siRNA, in cell cultures and was absent in gp91phox-/Y (Nox2 knock-out; KO) mice. Using pharmacological inhibitors, we show that ROS generated by Nox activation mobilizes Ca2+ flux from the cytosol to mitochondria, leading to S-glutathionylation of 75- and 50-kDa proteins of the complex I and inhibition of complex I activity, which results in elevated mitochondrial ROS. Systemic administration of mito-tempol prevented the sustained but not the acute elevations of blood pressure in IH-treated rats, suggesting that mitochondrial-derived ROS contribute to sustained elevation of blood pressure. Antioxid. Redox Signal. 14, 533–542.
Sleep disordered breathing manifested as recurrent apneas is characterized by transient, repetitive cessations of breathing (~10–15s in adults), resulting in periodic decreases in arterial blood O2 or intermittent hypoxia (IH). Patients with recurrent apneas develop several comorbidities, including hypertension, sympathetic activation, and abnormalities of breathing. (24). Studies on adult and neonatal rodent models suggest that reactive oxygen species (ROS) mediate many of the systemic responses to IH, including hypertension, sympathetic activation [reviewed in refs. (29, 35)], alterations in carotid body function (26, 27, 30), increase in catecholamine secretion from the adrenal chromaffin cells (14, 33), and changes in breathing (25). In addition, ROS signaling has also been implicated in activation of transcriptional factors and second messengers in IH-treated cell cultures (38, 39). Together, these studies suggest that ROS signaling mediates systemic and cellular responses to IH.
Membrane or cytosolic oxidases are the major sources for enzymatic generation of ROS (18). Recent studies implicated NADPH oxidases (Nox), especially Nox2 (also called gp91phox), in IH-evoked changes in sleep behavior (40), sensory long-term facilitation of the carotid body (27), and plasticity of respiratory behavior (22). Besides oxidases, mitochondrial electron transport chain complexes also generate ROS (17, 23). For instance, mitochondrial complex I (E.C 220.127.116.11, proton-translocating NADH:ubiquinone oxidoreductase), which is responsible for the oxidation of NADH by ubiquinone, is a major source of mitochondrial ROS (41). We have previously reported selective inhibition of mitochondrial complex I, but not the complex III in IH-treated rodents (27) and cell cultures (38). However, the mechanism(s) by which IH inhibits complex I activity have not been examined. Given that mitochondrial complex I activity can be altered by the redox state (32), we hypothesized that Nox activation and the resulting ROS mediates IH-induced inhibition of complex I. We tested this possibility in IH-treated cell cultures and mice deficient in Nox function. Our results demonstrate that ROS generated by Nox, especially Nox2, inhibit complex I activity via Ca2+-dependent S-glutathionylation of complex I subunits resulting in elevated mitochondrial ROS levels. More importantly, our data further showed that selective scavenging of mitochondrial ROS prevents IH-induced sustained but not transient elevation of blood pressure in rats.
PC12 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% horse serum, 5% fetal bovine serum (FBS), penicillin (100U/mL), and streptomycin (100μg/mL) under 10% CO2 and 90% air (20% O2) at 37°C. Before all experiments, the cells were serum starved for 16h in antibiotic-free medium to avoid any confounding effects of serum. In the experiments involving treatment with drugs, cells were preincubated for 30min with either drug or vehicle. Cell cultures were exposed to IH (1.5% O2 for 30s followed by 20% O2 for 5min at 37°C) as described previously (38, 39). O2 levels were monitored by an electrode (Lazar) placed in the tissue culture medium and ambient O2 levels were monitored by an O2 analyzer (Beckman LB2).
Complex I activity (NADH-ubiquinone reductase) was measured as rotenone (50μM)-sensitive rate of NADH oxidation and expressed in nanomoles of NADH oxidized per min per mg protein as previously described (38). Protein analysis was performed using Bio-RAD protein assay kit.
PC12 cells (5×105) were plated on collagen type IV (BD Biosciences)-coated culture dish and were grown for 24h. The transfection was performed with siRNAs specific for Nox2, Nox4, or scrambled (control) sequences (Santa Cruz Biotechnology; Cat # sc-61838 (Nox2), sc-61887 (Nox4), and sc-37007 Scrambled; 100pmol/mL) using a DharmaFECT-2 (Dharmacon Research) according to the manufacturer's recommendations. After transfection, cells were grown in the medium containing serum and antibiotics for 48h before subjecting to either 60 cycles of IH or normoxia.
Membrane-enriched fractions from PC12 cells and brain were isolated as described (19). NADPH oxidase activity in the membrane-enriched protein fractions was measured using cytochrome c reduction assay as described (20). Briefly, the assay medium contained 100μg membrane protein, cytochrome c, and NADPH at a final concentration of 150 and 100μM, respectively, and 25mM modified HEPES buffer (pH 7). The assay was performed in the presence and absence of superoxide dismutase (200 units/mL) at 37°C for 30min. Cytochrome c reduction was measured by reading absorbance at 550nm on a microplate reader. The amount of SOD inhibitable NADPH oxidase activity was calculated using extinction coefficient of 21mmol/(L cm) and expressed in nmol/min/mg protein.
Mitochondrial fractions were isolated from cells or brain extracts by differential centrifugation as described (15). Aconitase enzyme activity was determined in the mitochondrial fractions as described (38) and expressed as nanomoles of isocitrate formed per minute per milligram of protein.
Cells were lysed in Mannitol/Tris/EDTA (MTE) buffer and mitochondrial fractions were isolated by differential centrifugation. The mitochondrial pellet was solubilized in 20mM N-dodecyl-β-d-maltopyranoside (1% final concentration) and centrifuged at 72,000 g for 30min. Immune complexes were precipitated from the supernatant using anticomplex I monoclonal antibody (Mitosciences, Eugene, OR) and Protein A/G agarose beads. Complexes were eluted from the beads using SDS buffer without mercaptoethanol and analyzed on 10% SDS-PAGE nonreducing gels and transferred to a polyvinylpyrrolidone difluoride membrane (Immobilon-P; Millipore). Membranes were incubated with antireduced form of glutathione (GSH) mouse monoclonal antibody (Virogen) at 1:1000 dilution of stock in Tris-buffered saline- Triton x-100 containing 3% nonfat milk after overnight blocking in 5% milk. Membranes were treated with goat anti-mouse secondary antibody conjugated with horseradish peroxidase (dilution 1:2,000; Chemicon) and immune complexes were observed using enhanced chemiluminescence (ECL) detection system (Amersham BioSciences). The membranes were exposed to Kodak XAR films.
GSH and oxidized glutathione levels were determined in PC12 cells using Glutathione assay kit (#703002; Cayman Chemicals). The sulfhydryl group of GSH reacts with DTNB (5,5′-dithio-bis-2-nitrobenzoic acid, Ellman's reagent) to produce a yellow-colored 5-thio-2-nitrobenzoic acid (TNB) product, the absorbance of which is measured at 405nm. The rate of TNB production is directly proportional to the concentration of GSH. Quantification of oxidized from of glutathione (GSSG) exclusive of GSH is done by first derivatizing GSH with 2-vinylpyridine as described in the kit.
Experiments were approved by the Institutional Animal Care and Use Committee of the University of Chicago and were performed on adult male rats (200–300g; Sprague Dawley), wild type (Wt, C57BL/6), hemizygous gp91phox–/Y (from Jackson Laboratories; weights 20–25gm). Rats were treated with mito-tempol (10mg/Kg; intraperitoneal [IP]), a selective scavenger of mitochondrial ROS or apocynin (10mg/kg; IP) every day before 8h regimen of IH treatment for 10 days. Unrestrained, freely moving animals housed in feeding cages were exposed to intermittent hypoxia for 10 days (IH; 8h/day) as previously described (25–27). Briefly, animals were placed in a specialized chamber, which was flushed with alternating cycles of pure nitrogen and compressed air. During hypoxia, inspired O2 levels reached 5% O2 (nadir). The gas flows were regulated by timer-controlled solenoid valves. Ambient O2 and CO2 levels in the chamber were continuously monitored by an O2/CO2 analyzer (Series 9500; Alpha Omega Instrument). Control experiments were performed on animals exposed to alternating cycles of compressed room air instead of hypoxia in the same chamber. Blood pressures were monitored by the tail cuff method in unanaesthetized rats using a noninvasive BP system (AD Instruments) as described (28). Rats were placed in the restrainer provided by the manufacturer and were allowed to acclimate for at least 1h before blood pressure measurements. Baseline blood pressures were determined for 3 consecutive days in the morning (9 a.m.) and in the evening (5 p.m.). Subsequently, rats were exposed to IH for 10 days. Blood pressures were determined at the end 10th day within 1 and 15h after terminating IH.
All chemicals were of analytical grade and obtained from commercial sources. Mito-tempol was prepared in the laboratories of Drs. Joseph and Kalyanaraman.
The data were expressed as mean±SEM from at least three individual experiments. Two-way analysis of variance with repeated measures followed by Tukey's test was used to evaluate the statistical significance and p-values <0.05 were considered significant.
Nox and mitochondrial complex I activities were determined in PC12 cells treated with increasing durations of IH. Nox activity increased progressively in membrane fractions with increasing the duration of IH from 10, 30, and 60 cycles (Fig. 1A). Analysis of Nox activity using whole cell also revealed similar increase in response to IH (data not shown). Analysis of complex I activity in mitochondrial fractions showed progressive decrease with increasing the duration of IH (Fig. 1B). After re-oxygenation, Nox activity returned to baseline values within 3h (Fig. 1A), whereas complex I activity remained downregulated significantly even after 24h of re-oxygenation (p<0.05; Fig. 1B).
To assess whether Nox activation mediates IH-evoked complex I inhibition, PC12 cells were treated with two structurally distinct Nox inhibitors, apocynin (500μM) or 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride (300μM). Cells treated with Nox inhibitors were challenged with 60 cycles of IH (i.e., IH60; the maximum duration of IH used in this study). Both Nox inhibitors prevented IH60-evoked Nox activation and complex I inhibition (Fig. 2A, B).
Among the several isoforms of Nox (1), Nox2 mediates IH-evoked cellular responses in PC12 cells (39) and systemic responses in mice (27). The Nox inhibitors used in the above experiments cannot distinguish between different Nox isoforms. Therefore, siRNA approach was employed to assess the contribution of Nox 2 to IH-evoked complex I inhibition. Nox2 and Nox4 proteins were upregulated in IH-treated cells and this response was absent in cells transfected with Nox2 and Nox4 siRNAs (Fig. 2C; top panel). More importantly, IH-evoked inhibition of complex I activity was absent in cells treated with Nox2 but not Nox4 siRNA (Fig. 2C; bottom panel).
To further establish a role for Nox2 in IH-induced complex 1 inhibition, experiments were performed on age-matched wild-type (Wt) and hemizygous gp91phox–/Y mice (i.e., Nox2 knock-out mice) treated with 10 days of IH, a duration chosen based on previous study (28). Nox and complex I activities were analyzed in brain stem samples from both groups of mice, We chose the brain stem region because it provides adequate amount of tissue for biochemical assays and neurons in this region mediate increased sympathetic tone, which is a hallmark of IH [reviewed in ref. (29)]. Nox activity was significantly elevated in IH-treated Wt mice but not in Nox2 KO mice (Fig. 2D). As in PC12 cells, mitochondrial complex I activity was inhibited in IH-treated Wt mice and remarkably this response was absent in Nox2 KO mice (Fig. 2E).
Ca2+ inhibits mitochondrial complex I activity (32). IH activates Nox and the ensuing ROS elevates basal [Ca2+]i levels in PC12 cells (39). We therefore reasoned that elevated cytosolic [Ca2+]i and the resulting Ca2+ entry into mitochondria inhibits complex I. To test this possibility, cells were treated with increasing concentrations (1, 3, and 10μM) of 1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid (BAPTA-AM), an intracellular Ca2+-chelator, and as shown in Figure 3A, 10μM BAPTA-AM completely prevented IH-induced complex I inhibition. Likewise, 10μM ruthenium red (RR) an inhibitor of mitochondrial Ca2+ uniporter, which mediates Ca2+entry into mitochondria, also prevented complex I inhibition in IH60-treated cells (Fig. 3A). Treating control cells with Ca2+ ionophore (1.4μM ionomycin) inhibited the complex I activity, and 10μM RR or BAPTA-AM prevented this effect (Fig. 3B).
To further assess the effects of Ca2+, complex I activity was determined in the presence of varying concentrations of Ca2+. Increasing the concentration of Ca2+ from 0–80μM progressively inhibited complex I activity in control cells with a Ki of 5.3+0.4μM and this effect was not seen in IH-treated cells (Fig. 4A). Analysis of complex I activity as a function of NADH concentration in the presence of 20μM Ca2+ (4xKi) revealed a ~2-fold reduction in Vmax and Km (Fig. 4B). The baseline Vmax and Km values in IH60-treated cells were significantly lower than control cells but quite similar to those in Ca2+-treated control cells (Vmax: IH60=20.92±0.14 vs. Control+20μM Ca2+=23.32±0.20nmol/min/mg; Km: IH60=59.24±3.68 vs. Control+20μM Ca2+=69.50±2.02μM). Addition of 20μM Ca2+ had no further effect on either Vmax or Km in IH60-treated cells (Fig. 4C).
Ca2+-induced inhibition of the complex I activity can be reversed by sulfhydryl reducing agents, suggesting that oxidative modification of sulfhydryl residues leads to inhibition of complex I (34). S-glutathionylation of 75-kDa protein of complex I subunit represents one such sulfhydryl modification reaction (12). We monitored S-glutathionylation of 75-kDa and ~50kDa complex I proteins in control and IH60-treated cells. Mitochondrial complex I proteins were immunoprecipitated and probed with anti-glutathione antibody. S-glutathionylation of 75- and 50-kDa subunits of complex I increased by 2.5- and 3.5-fold, respectively, in IH60-treated cells compared with control cells (Fig. 5A; panel 1). Similar increases in S-glutathionylation of complex I subunits were also seen in control cells challenged with a Ca2+ ionophore (1.4μM ionomycin) (Fig. 5A, panel 2). RR (10μM) prevented the increase in S-glutathionylation of complex I subunits in IH60 as well as ionomycin-treated control cells (Fig. 5A, panels 1 and 2).
IH-evoked S-glutathionylation of complex I subunits was absent in PC12 cells treated with 500μM apocynin or manganese(III) tetrakis(1-methyl-4-pyridyl)porphyrin, a ROS scavenger or transfected with Nox2 siRNA (Fig. 5A; panels 3 and 4). Further, IH treatment also increased S-glutathionylation of mitochondrial complex I subunits in brain stem tissues from Wt mice and this effect was absent in tissues from Nox2 KO mice (Fig. 5A, panel 5). In addition, treatment of cells with N-acetyl-cysteine, a precursor of glutathione, also prevented IH-induced S-glutahtionylation of complex I subunits (Fig. 5A, panel 6).
S-glutathionylation requires oxidation of glutathione to glutathione disulfide (GSSG). Therefore, we determined whether IH affects the ratio of GSSG/GSH and whether addition of GSH reverses the inhibition of complex I activity in IH60-treated cells. As shown in Figure 5B, ratio of GSSG/GSH increased by ~2-fold in IH60-treated cells compared with controls. Addition of GSH to mitochondrial fractions from IH60 cells restored the complex I activity in a concentration-dependent manner with a complete recovery occurring at 5mM GSH (Fig. 5C). Since oxidative modification of sulfhydryl residues leads to inhibition of complex I, reducing agents like dithiothreitol (DTT) should prevent IH-induced complex 1 inhibition. Indeed, treatment of cells with 1mM DTT prevented inhibition of complex I by IH (Fig. 5D).
Analysis of the complex I activity as a function of NADH in the presence and absence of 5mM GSH showed that GSH increased the Vmax of the reaction by 65% in IH60-treated cells, whereas it did not alter Vmax in the control cells (Fig. 6A, B). On the other hand, GSH did not affect the Km of NADH both in the control as well as IH60-treated cells (Fig. 6A, B).
We determined whether IH-evoked complex I inhibition increases ROS generation in the mitochondria. The aconitase enzyme activity was monitored in the mitochondrial fractions as an index of ROS generation (10). Mitochondrial aconitase activity progressively decreased as the duration of IH increased from 10 to 60 cycles and remained significantly inhibited even after 24h of re-oxygenation (Fig. 7A). IH-evoked inhibition of aconitase activity was prevented by Nox inhibitor (apocynin), Ca2+chelator (BAPTA-AM), RR, an inhibitor of mitochondrial Ca2+ uniporter, as well as by N-acetyl-cysteine, a precursor of GSH and by manganese(III) tetrakis(1-methyl-4-pyridyl)porphyrin, an antioxidant (Fig. 7B). Further, inhibition of mitochondrial aconitase activity was absent in cells transfected with Nox2 but not with Nox4 or scrambled siRNAs (Fig. 7C).
Previous studies reported that antioxidant treatment prevents IH-evoked hypertension in rodents [reviewed in refs. (29, 35)], suggesting a role for ROS signaling. To address the role of ROS generated by Nox and mitochondria in IH-evoked hypertension, rats were treated with apocynin (10mg/Kg; IP), a Nox inhibitor or mito-tempol (10mg/Kg; IP), a selective scavenger of mitochondrial ROS (21) each day before 8h regimen of IH treatment for 10 days. Blood pressures were monitored ~1 and ~15h after terminating the IH regimen in unsedated rats. The results are summarized in Figure 8A. In vehicle-treated IH rats, mean blood pressures were elevated measured after ~1 as well as ~15h after terminating IH. Mito-tempol treatment abolished sustained elevations in blood pressures measured at ~15h without affecting the blood pressure elevations seen within 1h after terminating IH. In contrast, apocynin treatment prevented both early (within 1h) and sustained (after 15h) elevations in blood pressure (Fig. 8A). Results similar to apocynin treatment were also obtained in Nox-2 KO mice (data not shown).
Mitochondrial aconitase and Nox activities were determined in brain stem samples from rats treated with IH alone or in combination with mito-tempol or apocynin. In mito-tempol-treated rats IH-evoked decreases in mitochondrial aconitase activity (index of ROS) and complex I activities were absent, whereas increased Nox activity was unaffected (Fig. 8B–D). On the other hand, apocynin treatment prevented IH-evoked decrease in mitochondrial aconitase and complex I activities as well as increased Nox activity (Fig. 8B–D).
The present study reveals three novel and mechanistically linked findings: (i) IH-evoked mitochondrial complex I inhibition requires ROS generation by Nox2 and S-glutathionylation of complex I subunits, (ii) inhibition of complex I increases mitochondrial ROS, and (iii) mitochondrial ROS contributes to sustained but not transient elevations in blood pressure in IH-treated rats.
We previously reported that IH activates Nox (26) and inhibits mitochondrial complex I activity (27) in the rat carotid body. However, carotid bodies being too small in size (weighing 50–80μg) precluded analysis of potential interactions between Nox and complex I. PC12 cells respond similarly to IH with increased Nox and decreased mitochondrial complex I activities (38, 39) (Fig. 1), which prompted us to assess the interactions between Nox and mitochondrial complex I in this cell line. We further verified the data from PC12 cell cultures with brain stem tissue from intact mice or rats and found that IH increased Nox and decreased complex I activities in both preparations. However, Nox activity measured in brainstem tissue was lower than in PC12 cells. It is likely that Nox is expressed in certain population of neurons or a subset of glial cells, whereas PC12 cells are a homogenous population. The heterogeneity of brain stem tissue might account for the relatively lower complex I and Nox activities compared to PC12 cell cultures. Further, we also found similar changes in Nox and complex 1 activity in cerebral cortical tissue samples from IH-treated rats and mice, suggesting that these responses can be seen in other neural tissues as well.
The following observations demonstrate that activation of Nox, especially Nox2 by IH, mediates complex I inhibition: (a) two structurally distinct inhibitors of Nox prevented IH-evoked inhibition of complex I; (b) genetic silencing of Nox2 but not Nox 4 abrogated complex I inhibition in IH-treated cells, and (c) complex I inhibition by IH was absent in tissues from Nox2 KO mice. Consistent with previous studies (3, 5, 7, 13) we found that activation of Nox increases mitochondrial ROS. It has been proposed that mitochondrial permeability transition pore (mPTP) plays a critical role in mitochondrial redox signaling (6, 11, 21). The possibility that IH-induced mitochondrial ROS might be due to changes in mPTP requires further investigation. The finding that Nox activation by IH causes mitochondrial complex I inhibition under IH is reminiscent of mitochondrial dysfunction by Nox activation by angiotensin (37) and nitoglycerine (36). Nox activation by IH was transient and reversible, whereas complex I inhibition was long lasting. It is likely that transient Nox activation by IH and the ensuing ROS triggers prolonged ROS generation by mitochondria via inhibition of complex I activity. In other words, these data indicate that IH evokes ROS-induced ROS mechanism. Taken together these observations demonstrate a functional cross-talk between Nox and mitochondrial complex I activity under IH leading to mitochondrial dysfunction. Whether increased mitochondrial ROS impacts Nox activation as proposed recently (16, 31) also plays a role in IH remain to be investigated.
Our results provide further insight into how Nox activation by IH inhibits complex I. Yuan et al. (39) reported that ROS generated by Nox leads to persistent elevation of baseline [Ca2+]i in IH-treated PC12 cells. The following observations demonstrate that Ca2+ is critical for evoking complex I inhibition in IH-treated cells: (a) BAPTA-AM, a Ca2+ chelator or RR, an inhibitor of mitochondrial Ca2+ uniporter prevented IH-evoked complex I inhibition; (b) ionomycin, a Ca2+ ionophore inhibited complex I activity in control cells and this effect was prevented by RR; and (c) Ca2+ inhibited the complex I activity in control cells, and this effect was occluded in IH-treated cells. It can be argued that RR may inhibit Ca2+ release from the sarcoplasmic reticulum as evidenced in normal cardiomyocytes (4). However, RR at the concentrations that prevented complex I inhibition in IH-treated cells had no impact on complex I activity in control PC12 cells. Taken together, these observations suggest that Ca2+ entry into mitochondria is critical for complex I inhibition in IH-treated cells.
How might Ca2+ inhibit the mitochondrial complex I activity? Previous studies identified two catalytically distinct forms of mitochondrial complex I, including an active A-form and the other deactivated D-form (8). Ca2+ and other divalent cations facilitate the transition of active-to-deactivated form of the complex I with altered substrate affinity (9). IH decreased the substrate affinity of the complex I similar to that seen in control cells treated with Ca2+, suggesting that IH causes Ca2+-dependent conformational change in complex I similar to that reported with ischemia and re-perfusion in rat heart preparation (32). Previous studies have shown that the deactivated, not the active, form of the complex I is susceptible to redox modifications (8). Indeed IH caused redox modulation of modification of complex I as evidenced by increased S-glutathionylation of 75 and 50kDa subunits both in cell cultures and in the brain tissues from IH-treated mice. The findings that IH-evoked S-glutathionylation can be blocked by a Ca2+chelator as well as RR and mimicked by a Ca2+ ionophore further support the notion that IH-induced S-glutationylation involves a Ca2+-dependent conformational change of complex I subunits.
S-glutathionylation, in addition to conformational change of the complex I, also requires elevated GSSG levels (2). Not only did IH elevate GSSG as evidenced by increased ratio of GSSG/GSH, but more importantly, addition of GSH (reduced form) abrogated complex I inhibition and restored the Vmax of the reaction in IH-treated cells. These results demonstrate that S-glutathionylation is the critical signaling event responsible for IH-evoked complex I inhibition. The findings that IH-evoked S-glutathionylation could be prevented by a Nox inhibitor as well as by genetic silencing of Nox 2 in cell cultures and was absent in IH-treated Nox2 KO mice suggest that Nox 2 activation by IH and the resulting ROS mediate S-glutathionylation.
IH increased mitochondrial ROS, as evidenced by decreased mitochondrial aconitase activity, an in vivo marker of ROS. This increase in mitochondrial ROS was due to complex I inhibition, because preventing complex I inhibition abrogated the changes in mitochondrial aconitase activity. What might be the physiological significance of increased mitochondrial ROS by IH? One of the hallmarks of IH is the elevated blood pressures [reviewed in (29) and the present study]. Although ROS signaling has been implicated in IH-induced hypertension (28, 35), the relative importance of mitochondrial ROS has not been established. Our results showed that treatment with mito-tempol, a mitochondrial ROS scavenger, selectively abolished sustained but not the acute elevations of blood pressure in IH-treated rats, suggesting a role for mitochondrial ROS in IH-evoked hypertension. On the other hand, Nox inhibition by apocynin prevented both the transient as well as sustained elevations in blood pressures. Although cellular mechanisms by which mitochondrial ROS contribute to sustained elevations in blood pressure in IH-treated rats remain to be investigated, our results suggest a role for mitochondrial ROS generated by complex I inhibition resulting from Nox activation in mediating IH-induced long-lasting elevations of blood pressures.
This work was supported by National Institutes of Health–National, Heart, Lung, and Blood Institute Grants HL-90554, HL-76537, and HL-86493.
No competing financial interests exist.